MedTrace Logo

MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.

NCT07391839 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-02-06

No results posted yet for this study

Summary

The main purpose of the study is to evaluate the safety and efficacy of MDN-001 injection(Yttrium-90 Microsphere Injection)in the treatment of unresectable hepatocellular carcinoma. Other purposes of this study include assessment of the effect of treatment on overall survival, the length of time it takes for the disease to worsen, if and how the treatment affects the patient's quality of life, and if and how the cancer responds to the treatment.

Conditions

  • Hepatoma
  • Unresectable Hepatocellular Carcinoma (HCC)

Interventions

DRUG

MDN-001 Injection(Yttrium-90 Microsphere Injection)

Yttrium-90 Microsphere Injection

Sponsors & Collaborators

  • Suzhou Mednovo Yi Medical Technology Co., Ltd.

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-04
Primary Completion
2026-08-30
Completion
2027-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07391839 on ClinicalTrials.gov